40
Participants
Start Date
October 28, 2008
Primary Completion Date
March 23, 2017
Study Completion Date
March 23, 2017
radiotherapy (RT) in combination with temozolomide and bevacizumab
"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan-Kettering Cancer Center at Commack, Commack
Memoral Sloan Kettering Cancer Center, Basking Ridge
Collaborators (1)
Genentech, Inc.
INDUSTRY
National Institutes of Health (NIH)
NIH
Memorial Sloan Kettering Cancer Center
OTHER